CRL

NYSE

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Health Care, Life Sciences Tools & Services

$267.49

close 7 Aug 2026

+79.61%

52-week change

$12.77B

market cap

$144.26

$268.00

52-week range

Valuation

Market cap$12.77B

P/E (TTM / 5y avg)-55.73x75.50x

Forward P/E (FY2026 / FY2027)23.76x21.18x

PEG (TTM / fwd)—1.95

P/S (TTM)3.19x

P/B4.50x

EV/EBITDA (TTM)39.17x

FCF yield (TTM)2.90%

Cash flow & dividend

FCF (TTM)$370.61M

FCF per share (TTM)$7.76

FCF margin (TTM)9.27%

Dividend yield (indicated / 5y avg)——

Annualized dividend—

Payout ratio (EPS / FCF)——

Growth & quality

Revenue YoY, latest Q-2.72%

Diluted EPS YoY, latest Q-102.83%

Operating margin (TTM)2.25%

Net margin (TTM)-5.96%

ROE (latest FY)-4.56%

Net debt / EBITDA (TTM)6.27

Interest coverage (TTM)0.85

Price

-34.95%-8.27%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +6.55%10Y CAGR +11.41%

Diluted EPS

FCF per share

5Y CAGR +6.84%10Y CAGR +7.43%

Operating cash flow

5Y CAGR +6.18%10Y CAGR +9.17%

Free cash flow

5Y CAGR +6.41%10Y CAGR +7.85%

Operating margin

FCF margin

Return on equity

Return on capital employed

Shares outstanding

5Y CAGR -0.22%10Y CAGR +0.53%

Net debt / EBITDA

Interest coverage

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date3 Nov 2026bmo

EPS estimate$3.08

Revenue estimate$947.15M

Last reported

Date—

EPS——

Revenue——